Therapeutic potential of induced and natural FoxP3(+) regulatory T cells for the treatment of Graft-versus-host disease

Immo Prinz; Christian Koenecke

doi:10.1007/s00005-012-0172-3

Therapeutic potential of induced and natural FoxP3(+) regulatory T cells for the treatment of Graft-versus-host disease

Standard

Therapeutic potential of induced and natural FoxP3(+) regulatory T cells for the treatment of Graft-versus-host disease. / Prinz, Immo; Koenecke, Christian.

In: ARCH IMMUNOL THER EX, Vol. 60, No. 3, 06.2012, p. 183-90.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Prinz, I & Koenecke, C 2012, 'Therapeutic potential of induced and natural FoxP3(+) regulatory T cells for the treatment of Graft-versus-host disease', ARCH IMMUNOL THER EX, vol. 60, no. 3, pp. 183-90. https://doi.org/10.1007/s00005-012-0172-3

APA

Prinz, I., & Koenecke, C. (2012). Therapeutic potential of induced and natural FoxP3(+) regulatory T cells for the treatment of Graft-versus-host disease. ARCH IMMUNOL THER EX, 60(3), 183-90. https://doi.org/10.1007/s00005-012-0172-3

Vancouver

Prinz I, Koenecke C. Therapeutic potential of induced and natural FoxP3(+) regulatory T cells for the treatment of Graft-versus-host disease. ARCH IMMUNOL THER EX. 2012 Jun;60(3):183-90. https://doi.org/10.1007/s00005-012-0172-3

Bibtex

@article{cbf99bd3976545e1b1a9b36872876a4f,

title = "Therapeutic potential of induced and natural FoxP3(+) regulatory T cells for the treatment of Graft-versus-host disease",

abstract = "Graft-versus-host disease (GvHD) remains a major complication after allogeneic hematopoietic stem-cell-transplantation. Present GvHD prophylaxis and treatment is still based on unspecific immunosuppressive drug therapy. Over the last decade, the potential of cell-based therapies involving the infusion of regulatory T cells has emerged as a feasible alternative approach for the treatment and prevention of GvHD. Here we review current efforts to translate data obtained in rodent models into clinical trials. Special emphasis is placed on the variety of strategies to generate sufficient numbers of alloantigen-specific regulatory T cells for adoptive cell therapy. This can be achieved either by expansion or by induction of a regulatory phenotype in naive T cells. Stability of the immunosuppressive phenotype of transferred regulatory T cells even in the highly inflammatory environment of acute GvHD will be thereby a critical parameter for actual therapeutic application.",

keywords = "Adoptive Transfer/methods, Animals, Cells, Cultured, Clinical Trials as Topic, Forkhead Transcription Factors/immunology, Graft vs Host Disease/etiology, Hematopoietic Stem Cell Transplantation/adverse effects, Humans, Isoantigens/immunology, Lymphocyte Activation/immunology, Mice, T-Lymphocytes, Regulatory/immunology",

author = "Immo Prinz and Christian Koenecke",

year = "2012",

month = jun,

doi = "10.1007/s00005-012-0172-3",

language = "English",

volume = "60",

pages = "183--90",

journal = "ARCH IMMUNOL THER EX",

issn = "0004-069X",

publisher = "Birkhauser Verlag Basel",

number = "3",

}

RIS

TY - JOUR

T1 - Therapeutic potential of induced and natural FoxP3(+) regulatory T cells for the treatment of Graft-versus-host disease

AU - Prinz, Immo

AU - Koenecke, Christian

PY - 2012/6

Y1 - 2012/6

N2 - Graft-versus-host disease (GvHD) remains a major complication after allogeneic hematopoietic stem-cell-transplantation. Present GvHD prophylaxis and treatment is still based on unspecific immunosuppressive drug therapy. Over the last decade, the potential of cell-based therapies involving the infusion of regulatory T cells has emerged as a feasible alternative approach for the treatment and prevention of GvHD. Here we review current efforts to translate data obtained in rodent models into clinical trials. Special emphasis is placed on the variety of strategies to generate sufficient numbers of alloantigen-specific regulatory T cells for adoptive cell therapy. This can be achieved either by expansion or by induction of a regulatory phenotype in naive T cells. Stability of the immunosuppressive phenotype of transferred regulatory T cells even in the highly inflammatory environment of acute GvHD will be thereby a critical parameter for actual therapeutic application.

AB - Graft-versus-host disease (GvHD) remains a major complication after allogeneic hematopoietic stem-cell-transplantation. Present GvHD prophylaxis and treatment is still based on unspecific immunosuppressive drug therapy. Over the last decade, the potential of cell-based therapies involving the infusion of regulatory T cells has emerged as a feasible alternative approach for the treatment and prevention of GvHD. Here we review current efforts to translate data obtained in rodent models into clinical trials. Special emphasis is placed on the variety of strategies to generate sufficient numbers of alloantigen-specific regulatory T cells for adoptive cell therapy. This can be achieved either by expansion or by induction of a regulatory phenotype in naive T cells. Stability of the immunosuppressive phenotype of transferred regulatory T cells even in the highly inflammatory environment of acute GvHD will be thereby a critical parameter for actual therapeutic application.

KW - Adoptive Transfer/methods

KW - Animals

KW - Cells, Cultured

KW - Clinical Trials as Topic

KW - Forkhead Transcription Factors/immunology

KW - Graft vs Host Disease/etiology

KW - Hematopoietic Stem Cell Transplantation/adverse effects

KW - Humans

KW - Isoantigens/immunology

KW - Lymphocyte Activation/immunology

KW - Mice

KW - T-Lymphocytes, Regulatory/immunology

U2 - 10.1007/s00005-012-0172-3

DO - 10.1007/s00005-012-0172-3

M3 - SCORING: Review article

C2 - 22476537

VL - 60

SP - 183

EP - 190

JO - ARCH IMMUNOL THER EX

JF - ARCH IMMUNOL THER EX

SN - 0004-069X

IS - 3

ER -